[Personalized medicine and prostate cancer. The reality of change].

[Personalized medicine and prostate cancer. The reality of change]. Arch Esp Urol. 2015 Apr;68(3):391-400 Authors: Carballido Rodríguez JA, Martínez-Salamanca JI Abstract Prostate cancer (PCa) is a public health problem in western male populations on the basis of it's high incidence and prevalence. Nowadays we come to changes in the diagnostic technologies that deserve special attention and that once applied allow to show the way towards a personalized view of PCa being able to join this modern current trend of the oncologic pathology. In spite of the recognized heterogeneity of the disease; clinical, pathological and genetic variants in genes and the limitations of the PSA as a biomarker to determine the biological aggressiveness of PCa, the certain thing is that the therapeutic final decision is adopted on the basis of a distant information to the wished customization and it moves excessive uncertainty for patients.In this respect the search based on the identification of alterations on the genomic sequence and it's influence in the molecular characterization of the PCa is a constant in the investigation since nowadays. Actually, the progressive adjournment to the clinic of information tumour information that comes from the diagnostic tests related genetic material or their biochemical products, though still in initial phase, already allows to predict relevant changes in molecular characterization of the prostate cancer, in the e...
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research